Building tomorrow's
breakthroughs

Panacea Venture is a life sciences venture fund with global vision and reach dedicated to transforming lives through promising innovation

down arrow

About our
investment firm

Spun out from Kleiner Perkins, the founding partners sought to build a global firm, investing in innovation in every geography, while bringing its unique perspectives in life sciences experience to benefit global company building.

To date, Panacea Venture raised three USD funds from renowned institutional funds as well as strategic investors and has investments in more than 30 private companies and several public companies.

More about us

Portfolio

Panacea incubates early-stage companies with breakthrough technologies and discoveries that can potentially address unmet medical needs to enhance quality of life on a global scale.

Our approach

We build and capture value from company formation to expansion stage to public market investing.

35+

Companies

19+

Partners and
Venture Partners

100+

Years of experience

Recent news

Recent news about Panacea Venture and select portfolio companies.

Browse all articles
June 16, 2025

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.

June 16, 2025

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.

June 16, 2025

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

Marcy l’Étoile, France – June 16th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance  … Read more

June 16, 2025

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

Marcy l’Étoile, France – June 16th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance  … Read more